Carprodyl Quadri 120 mg Chewable Tablets for Dogs

Land: Storbritannien

Sprog: engelsk

Kilde: VMD (Veterinary Medicines Directorate)

Aktiv bestanddel:

Carprofen

Tilgængelig fra:

Ceva Animal Health Ltd

ATC-kode:

QM01AE91

INN (International Name):

Carprofen

Lægemiddelform:

Chewable tablet

Recept type:

POM-V - Prescription Only Medicine – Veterinarian

Terapeutisk gruppe:

Dogs

Terapeutisk område:

Anti Inflammatory NSAID

Autorisation status:

Authorized

Autorisation dato:

2010-02-04

Produktets egenskaber

Revised: September 2022
AN: 01545/2022
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprodyl Quadri 120 mg chewable tablets for Dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
One tablet contains:
Carprofen.........................................................120
mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet.
Clover-shaped scored beige tablet
The tablet can be divided into four equal parts.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In the dog:
Reduction of inflammation and pain caused by musculo-skeletal
disorders and
degenerative joint disease.
As a follow-up to parenteral analgesia in the management of
post-operative pain.
4.3
CONTRAINDICATIONS
Do not use in pregnant and lactating bitches.
Do not use in dogs aged less than 4 months in the absence of specific
data.
Do not use in cats.
Do not use in dogs, suffering from cardiac, hepatic or renal disease,
when there is a
possibility of gastrointestinal ulceration or bleeding or where there
is evidence of
blood dyscrasia.
Do not use in case of hypersensitivity to the active substance, to
other NSAID and to
any of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
See sections 4.3 and 4.5.
Revised: September 2022
AN: 01545/2022
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional risk. If
such a use cannot be avoided, dogs may require a reduced dosage and
careful
clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a
potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAID can cause inhibition of phagocytosis and hence in the treatment
of inflammatory
conditions
associated
with
bacterial
infection,
appropriate
concurrent
antimicrobial
therapy should be instigated.
As